N-[5-(3,4-dichloro-phenyl)-2H-pyrazol-3-yl]4,4,4-trifluoro-3-oxo-butyramide | 569656-08-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-[5-(3,4-dichloro-phenyl)-2H-pyrazol-3-yl]4,4,4-trifluoro-3-oxo-butyramide
• 英文别名: N-[5-(3,4-dichlorophenyl)-1H-pyrazol-3-yl]-4,4,4-trifluoro-3-oxobutanamide
• CAS: 569656-08-2
• 化学式: C₁₃H₈Cl₂F₃N₃O₂
• 分子量: 366.127
• InChiKey: MZQQJOFSEZRXQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  74.8
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  氨基硫脲 、 3,4-二氯苯乙酮 以 乙醇 、 氯仿 、 溶剂黄146 为溶剂， 以2.47 g (89%)的产率得到N-[5-(3,4-dichloro-phenyl)-2H-pyrazol-3-yl]4,4,4-trifluoro-3-oxo-butyramide
  参考文献：
  名称：

  Methods of treating conditions associated with an EDG-4 receptor

  摘要：

  本发明提供了一种调节细胞中Edg-4受体介导的生物活性的方法。将表达Edg-4受体的细胞与足以调节Edg-4受体介导的生物活性的调节剂接触。在另一个方面，本发明提供了一种调节受体Edg-4介导的生物活性的方法。向受体施用治疗有效量的Edg-4受体调节剂。

  公开号：

  US20050113283A1

文献信息

• Aminoisoxazole derivatives active as kinase inhibitors
  申请人：Cavicchioli Marcello

  公开号：US20050059657A1

  公开（公告）日：2005-03-17

  Compounds (I) which are aminoisoxazole derivatives or pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.

  本发明涉及氨基异噁唑衍生物(I)或其药学上可接受的盐，以及包含它们的药物组合物。这些化合物或组合物在治疗由蛋白激酶活性改变引起和/或相关的疾病方面具有用途，例如癌症、细胞增殖性疾病、阿尔茨海默病、病毒感染、自身免疫性疾病和神经退行性疾病。
• AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS
  申请人：Pharmacia Italia S.p.A.

  公开号：EP1435948A1

  公开（公告）日：2004-07-14
• METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR
  申请人：SRI INTERNATIONAL

  公开号：EP1513522A2

  公开（公告）日：2005-03-16
• [EN] AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'AMINOISOXAZOLE AGISSANT COMME INHIBITEURS DE LA KINASE
  申请人：PHARMACIA ITALIA SPA

  公开号：WO2003013517A1

  公开（公告）日：2003-02-20

  Compounds (I) which are aminoisoxazole derivatives or pharmaceutically acceptable salts thereof, together with pharmaceutical compositions comprising them are disclosed; these compounds or compositions are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders.
• [EN] METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR<br/>[FR] PROCEDES POUR TRAITER DES PATHOLOGIES ASSOCIEES A UN RECEPTEUR D'EDG
  申请人：CERETEK LLC

  公开号：WO2003062392A2

  公开（公告）日：2003-07-31

  The present invention provides a method of modulating an Edg-2, Edg-3, Ed-4 or Edg7 receptor mediated biological activity in a cell. A cell expressing the Edg-2, Edg-3, Edg-4 or Edg 7 receptor is contacted with a modulator of the Edg-2, Edg-3, Ed-4 or Edg 7 receptor sufficient to modulate receptor mediated biological activity. In another aspect, the present invention provides a method for modulating an Edg-2, Edg-3, Ed-4 or Edg-7 receptor mediated biological in a subject. A therapeutically effective amount of a modulator of the Edg-2, Edg-3, Ed-4 or Edg7 receptor is administered to the subject.